tiprankstipranks
Trending News
More News >

Tenax Therapeutics price target lowered to $15 from $16 at Guggenheim

Guggenheim analyst Seamus Fernandez lowered the firm’s price target on Tenax Therapeutics (TENX) to $15 from $16 and keeps a Buy rating on the shares. The firm, which is updating its model following the company’s Q1 results, looks forward to the Phase 3 LEVEL readout in 2026. The firm believes this data will be “a major catalyst from which we see the potential for at least a 2x stock move from current levels,” the analyst added.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1